Did you mean velneperit of s 2009 of ベルネペリット?
Displaying drugs 676 - 700 of 10637 in total
Rezafungin
Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week...
Approved
Investigational
Matched Description: … Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily ... [A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and ... L45633]
Clinical studies have shown that rezafungin is non-inferior to caspofungin for the treatment of …
Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Description: … Clinical trials suggest its efficacy in the treatment of partial seizures. ... derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of …
Goldenseal
Approved
Experimental
Novobiocin
Novobiocin is an antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189)
Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964...
Approved
Investigational
Vet approved
Withdrawn
Matched Description: … From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189)
Novobiocin sodium, a salt form of ... novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious ... infections due to susceptible strains of _Staphylococcus aureus_ when other less toxic antibiotics cannot …
Penbutolol
Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the...
Approved
Investigational
Matched Description: … This binding characteristic of penbutolol is being investigated for its implications in Antidepressant …
Tazobactam
Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.
Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved...
Approved
Matched Description: … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other ... It is combined with [Piperacillin] and [Ceftolozane] for the treatment of a variety of bacterial infections ... hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of …
Loxoprofen
Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation was approved for use in Japan in January 2006.
Approved
Relebactam
Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam.[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes imipenem and cilastatin to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated...
Approved
Investigational
Matched Description: … [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination …
Nedocromil
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Approved
Investigational
Matched Description: … A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with …
Baricitinib
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … baricitinib for the treatment of COVID-19 in May 2022. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of …
Degarelix
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in...
Approved
Matched Description: … Degarelix is used for the treatment of advanced prostate cancer. ... Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which …
Daridorexant
Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of ... Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin ... was designed via an intensive drug discovery program to improve the potency and maximize the duration of …
Propiolactone
Propiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes. It has been used against bacteria, fungi, and virus. It is currently...
Approved
Withdrawn
Matched Description: … Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, …
Edetic acid
A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Approved
Vet approved
Matched Description: … A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. …
Metreleptin
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia,...
Approved
Matched Description: … of adipose tissue. ... [L41315] Administration of metreleptin results in improvement of metabolic symptoms including improvements ... of leptin deficiency in people with lipodystrophy. …
Diroximel fumarate
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS...
Approved
Investigational
Matched Description: … of both North America and Europe. ... More than 80% of patients suffering from this disease have relapsing-remitting MS. ... Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. …
Methimazole
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Description: … Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones. ... first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of ... the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of …
Pralsetinib
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … RET RTK inhibitors for the treatment of RET-driven cancers. ... , [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of ... [A202049, A202055, L15986]
Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is …
Budesonide
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532]
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Description: … of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. ... Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions …
Tepotinib
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid ... [A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D ... [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a …
Nilutamide
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... the growth of normal and malignant prostatic tissue. ... Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. …
Defibrotide
Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of...
Approved
Investigational
Matched Description: … Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from ... It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. …
Potassium bicarbonate
Potassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid. It is registered in the FDA under the section of suitable, safe and effective ingredients for...
Approved
Matched Description: … It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. ... [T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for …
Lesinurad
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with...
Approved
Investigational
Matched Description: … Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia ... Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of ... It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake …
Lifitegrast
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Displaying drugs 676 - 700 of 10637 in total